^
    Back
    Association details:
    Biomarker:BRCA1 mutation + HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    For those with germline BRCA1/2 mutations and HR-positive, HER2-negative disease who received preoperative chemotherapy, consider adjuvant olaparib…